|
LIVE WEBINAR: Thursday, March 4, 2021, 5:00 PM – 6:15 PM Eastern Time
Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Urothelial Bladder Carcinoma (Part 3 of a 3-Part Series)A CME Webinar Series Held in Conjunction with the 2021 Genitourinary Cancers SymposiumRegister Now
Register for either or both the Feb 25 and Mar 4 complimentary events with the “Register Now” button above, Join us on Thursday, March 4th for this CME-accredited webinar Faculty
Arjun Balar, MD Associate Professor, Department of Medicine Director, Genitourinary Medical Oncology Program NYU Perlmutter Cancer Center New York, New York Elisabeth I Heath, MD Associate Center Director, Translational Sciences Chair, Genitourinary Oncology Multidisciplinary Team Professor of Oncology and Medicine Hartmann Endowed Chair for Prostate Cancer Research Director, Prostate Cancer Research Karmanos Cancer Institute Wayne State University School of Medicine Detroit, Michigan Jonathan E Rosenberg, MD Chief, Genitourinary Medical Oncology Service Division of Solid Tumor Oncology Enno W Ercklentz Chair Memorial Sloan Kettering Cancer Center New York, New York Moderator Neil Love, MD Research To Practice Miami, Florida Thursday, March 4, 2021 Agenda MODULE 1: Evolving Management of Nonmetastatic Urothelial Bladder Cancer (UBC)
MODULE 2: Current Approaches to the Treatment of Newly Diagnosed Metastatic UBC (mUBC)
MODULE 3: Selection and Sequencing of Therapy for Relapsed UBC
MODULE 4: New Directions in the Management of Advanced UBC
Target Audience
CME Credit Form Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement Research To Practice designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Balar — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Immunomedics Inc, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seagen Inc. Dr Heath — Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Sanofi Genzyme; Consulting Agreement: Astellas; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Caris Life Sciences, Celgene Corporation, Celldex Therapeutics, Corcept Therapeutics, CureMeta LLC, Dendreon Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Esanik Therapeutics, Fortis Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Ignyta Inc, Inovio Pharmaceuticals Inc, Medivation Inc, a Pfizer Company, Merck, Merck Sharp & Dohme Corp, Oncolys BioPharma, Plexxikon Inc, Seagen Inc, Synta Pharmaceuticals Corp, Takeda Oncology, Tokai Pharmaceuticals Inc, Zenith Epigenetics; Paid Travel: Astellas, Caris Life Sciences, Seagen Inc; Speakers Bureau: Sanofi Genzyme. Dr Rosenberg — Advisory Committee: Astellas, Seagen Inc; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Mirati Therapeutics, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, QED Therapeutics, Seagen Inc.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Astellas and Seagen Inc and Merck. |